Novoprotein(SH:688137)2024-10-29 11:26Financial Performance - The company's operating revenue for Q3 2024 was ¥32,423,821.44, representing a decrease of 9.98% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥9,352,741.32, a decline of 365.98% year-over-year[2]. - Total revenue for the first three quarters of 2024 was ¥92,079,068.48, a decrease of 16.8% compared to ¥110,706,893.65 in the same period of 2023[18]. - The company's net profit for the first three quarters was impacted by a significant increase in operating costs, leading to a net loss in the period[18]. - The net profit for Q3 2024 was -¥18,258,535.09, compared to a net profit of ¥15,876,672.69 in Q3 2023, indicating a significant decline[20]. - The total comprehensive income for Q3 2024 was -¥18,252,306.68, compared to ¥15,867,037.47 in the same period last year[21]. - Basic and diluted earnings per share for Q3 2024 were both -¥0.26, down from ¥0.23 in Q3 2023[21]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,243,590,370.36, down 2.41% from the end of the previous year[3]. - Total assets decreased to ¥2,243,590,370.36 from ¥2,298,915,220.36, a reduction of 2.4%[17]. - Total liabilities decreased slightly to ¥108,782,715.04 from ¥110,425,722.31, a decline of 1.5%[17]. - The company’s total equity decreased to ¥2,134,807,655.32 from ¥2,188,489,498.05, a decline of 2.5%[17]. - The total number of common shareholders at the end of the reporting period is 6,203[8]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥19,846,430.73, a decrease of 61.64% compared to the previous year[2]. - Cash flow from operating activities for the first three quarters of 2024 was ¥19,846,430.73, a decrease from ¥51,739,786.35 in the same period of 2023[24]. - The cash and cash equivalents at the end of Q3 2024 were ¥668,389,680.48, down from ¥1,641,813,148.80 at the end of Q3 2023[24]. - The company's cash and cash equivalents decreased to ¥668,950,856.76 from ¥863,702,581.67, reflecting a decline of 22.6%[15]. - The total operating cash outflow for Q3 2024 was ¥138,744,972.68, compared to ¥167,586,736.77 in Q3 2023[24]. Shareholder Information - The largest shareholder, Shanghai Xinbainuo Biotechnology Co., holds 30,355,000 shares, accounting for 43.26% of the total shares[8]. - The second-largest shareholder, Wujiang Dongyun Venture Investment Co., holds 10,120,000 shares, which is 14.42% of the total shares[8]. - The company has repurchased a total of 350,337 shares, representing 0.4992% of the total share capital of 70,175,439 shares[13]. - The highest repurchase price was RMB 33.00 per share, while the lowest was RMB 28.75 per share, with a total expenditure of RMB 10,346,681.909[14]. - The proportion of shares held by the top 10 shareholders is significant, with the top three holding over 60% of the shares[8]. Research and Development - Research and development expenses totaled ¥11,341,991.60 for the quarter, accounting for 34.98% of operating revenue, an increase of 1.94 percentage points year-over-year[3]. - Research and development expenses for the first three quarters were ¥33,757,447.63, a decrease of 9.8% compared to ¥37,204,713.45 in the previous year[18]. - The company has not disclosed any new product or technology developments in this report[10]. Market and Future Outlook - There is no indication of market expansion or mergers and acquisitions in the current reporting period[10]. - The company has not provided specific future guidance or performance outlook in this report[10]. - The company experienced a significant increase in unit product costs, contributing to the decline in net profit[6].